|
|
|
|
|
|
Sponsors and Collaborators: |
Elan Pharmaceuticals Biogen Idec |
Information provided by: | Elan Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00707512 |
The purpose of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events in patients with Crohn's Disease(CD) treated with TYSABRI® (Natalizumab)
Condition | Intervention |
Crohn's Disease |
Drug: Natalizumab |
Genetics Home Reference related topics: | Crohn disease |
MedlinePlus related topics: | Cancer Crohn's Disease |
Drug Information available for: | Natalizumab |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Estimated Enrollment: | 2000 |
Study Start Date: | June 2008 |
Estimated Primary Completion Date: | June 2017 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Specialty IBD clinics or GI clinical practices
Inclusion Criteria:
Exclusion Criteria:
United States, West Virginia | |||||
There may be multiple sites in this clinical trial. Please contact United BioSource Corporation | Recruiting | ||||
200 Pinecrest Plaza, Morgantown, West Virginia, United States, 26505 | |||||
Contact: Contact 888-613-7542 LSKC_CD_INFORM@unitedbiosource.com |
Elan Pharmaceuticals |
Biogen Idec |
Responsible Party: | ( Elan Pharmaceuticals ) |
Study ID Numbers: | ELN100226-CD451, CD INFORM |
First Received: | June 27, 2008 |
Last Updated: | July 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00707512 |
Health Authority: | United States: Food and Drug Administration |
|
|